Présentation de l'entreprise
XWELL, Inc. operates within the healthcare sector, specifically focusing on the diagnostics and research industry, providing a comprehensive suite of health and wellness services to travelers across the United States and international markets. The company's operational model is segmented into four distinct areas: XpresSpa, XpresTest, Naples Wax Center, and Treat, with the XpresSpa division offering specific traveler services such as massage, nail care, and skin treatments. As of the latest data, the enterprise carries a market capitalization of $7.55M and generated annual revenue of $29.21M, while the number of employees is listed as N/A. These financial figures indicate a small-cap profile typical of niche service providers, where the relatively modest market cap suggests a limited valuation multiple compared to large-cap peers, and the revenue scale reflects a specialized business model rather than broad consumer mass-market dominance. The absence of employee count data further limits the ability to assess labor density per revenue dollar, suggesting that traditional employment metrics may not be the primary driver of its current operational structure or reporting framework.
Santé financière
The company reported revenue of $29.21M for the trailing twelve months, yet recorded a net income of -$28.23M, creating a significant gap that reveals a highly aggressive cost structure where operating expenses substantially exceed gross profit generation. Additionally, the entity reported an EBITDA of -$8.49M, indicating that even before interest and taxes, the core business operations are currently generating a cash shortfall. Free cash flow stands at -$5.10M, which implies a lack of financial flexibility for capital expenditures, debt repayment, or dividend payments, necessitating reliance on external financing or cash reserves. The gross margin sits at 25.7%, while the operating margin is negative at -45.1% and the profit margin reaches -58.2%, collectively indicating that while the product or service pricing covers direct costs, overhead and administrative expenses are consuming the majority of revenue before any profit is realized. On the balance sheet, cash holdings of $2.62M are insufficient to cover total debt obligations of $12.49M, and with a debt-to-equity ratio listed as N/A, the leverage position cannot be fully quantified but appears heavily reliant on creditor funding given the negative equity implied by the negative book value metrics. The current ratio is 0.46, signaling a severe liquidity constraint where current assets do not cover current liabilities, raising concerns about the ability to meet short-term obligations without refinancing. Return on Equity is N/A due to negative shareholders' equity, while Return on Assets stands at -32.0%, revealing that management is currently destroying value relative to the asset base employed in the business.
Évaluation de la valorisation
The trailing P/E ratio is not available due to negative earnings, whereas the forward P/E is listed as -0.50, a metric that typically indicates negative expected earnings or a calculation anomaly in loss-making firms, making traditional earnings-based valuation comparisons difficult. The price-to-book ratio is -1.19, which indicates that the market values the company at less than zero times its book value, reflecting investor skepticism regarding the recoverability of assets or the ability to generate positive equity value in the near term. Alternative valuation metrics show a price-to-sales ratio of 0.26 and an EV/EBITDA of -3.52, suggesting that the market is pricing the stock primarily on revenue multiples rather than profitability, a common approach for pre-profitability growth or turnaround candidates. Technical price action shows a 52-week high of $2.20 and a 52-week low of $0.26, meaning the current share price is trading significantly below the recent peak, highlighting the substantial downside distance from the year's best level. The beta value of 0.96 suggests that the stock's price volatility tracks closely with the broader market movements, offering no significant hedge against systemic risk nor does it amplify market swings beyond the standard correlation coefficient of one.
Growth & Income
Revenue growth year-over-year is -4.2%, indicating a contraction in top-line sales, while earnings growth is N/A, preventing a direct comparison of efficiency improvements but implying that profitability has deteriorated alongside revenue. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it retains earnings that are currently negative, meaning the company is not distributing income to shareholders but rather reinvesting minimal resources or burning through cash reserves. The overall growth and income profile is characterized by negative revenue expansion and a complete absence of dividend income, positioning the equity as a speculative vehicle rather than an income-generating asset. This financial structure suggests that future performance hinges entirely on the ability to reverse the negative growth trend and achieve positive cash flows, as there are no dividend payouts to cushion investor returns during periods of market stagnation.